Akari Therapeutics has reaffirmed its commitment to advancing research on PH1, a novel spliceosome modulator payload used in […]

Collaboration aims to advance next-generation therapeutics and vaccines

First patient dosed in phase 1b/2a study of procizumab

Irish biotech’s germ-free egg platform could help close global shortfall

GlueSEEKER enables rational design of targeted protein degraders

Clinical results from phase 2 study highlight analgesic effects in neuropathic pain patients

EC grants conditional marketing authorisation to Merck and SpringWorks Therapeutics

First patient dosed in BUOY-1 study targeting MDD with or without anxious distress

Funding to accelerate development of AI-driven tumour profiling tool OneMap